MRNA Stock — Moderna Inc.

Moderna Inc. (MRNA)

Updated October 16, 2026.

MRNA is a Stock. Total return is 1072.1% over the past 7.9 years, 845.7 points ahead of SPY at 226.4%.

Moderna is a biotechnology company that develops and commercializes messenger RNA medicines, including respiratory vaccines (such as COVID-19 and RSV vaccines), latent virus vaccines, oncology therapeutics, and rare disease treatments. The company does not currently pay distributions to shareholders. Moderna operates primarily in the United States and Europe, with strategic partnerships including collaborations with Merck, Vertex Pharmaceuticals, and various public health organizations.

MRNA performance versus SPY

Price and return data through 2026-10-16.

Total return is 1072.1% over the past 7.9 years, 845.7 points ahead of SPY at 226.4%. Over the past year its total return — price change plus distributions reinvested — is 703.3%. Its deepest 1-year drawdown was 34.2%.

MRNA key facts

Asset type

Stock

Asset class

Equity

Inception date

12/07/2018

Distribution frequency

None

Last close

$218.01 (as of 2026-10-16)

Market cap

$87,037,416,161

Average volume

21334738.0

Beta

1.095

Payout ratio

0.0%

Forward P/E

23.0415

EPS

$-8.35

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MRNA risks and drawbacks

The deepest 1-year drawdown on record here is 34.2%.

Who may consider MRNA — and who may not

It is a weaker fit for investors who need monthly cash flow (MRNA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MRNA

• ETFs holding MRNA
• All tickers starting with M

Tagged: Healthcare.

Compare MRNA

MRNA vs similar funds:

• MRNA vs MRNY

Frequently asked questions